DUALITYBIO-B(09606.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
DUALITYBIO-B
09606.HK
Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It has strategic partnerships with BioNTech SE to develop therapies to complement or replace chemotherapy; and BeiGene, Ltd. to develop and commercialize DB-1312, an in-house discovered B7-H4- targeted ADC.
1.276 T
09606.HKMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BioNTech initiates the first Phase III clinical trial of B7-H3 ADC, expected to obtain results in January 2031

    BioNTech has initiated the first Phase III clinical trial of DB-1311/BNT324, expected to recruit 736 participants, with results to be announced in January 2031. BNT324 is a B7-H3 ADC developed by DUALITYBIO, which was licensed to BioNTech in April 2023, granting the latter development, production, and commercialization rights outside of China

    AASTOCKS·
    HK
    09606
    -1.07%
    AASTOCKS·
    HK
    09606
    -1.07%

    Guotai Haitong Sticks to Its Buy Rating for Duality Biotherapeutics, Inc. (9606)

    Guotai Haitong analyst maintained a Buy rating on Duality Biotherapeutics, Inc. yesterday and set a price target of HK$455.56.Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Duality Biotherapeutics, Inc. has an analyst consensus of Strong Buy, with a price target consensus of HK$488.96.

    Tip Ranks·
    HK
    09606
    -1.07%
    Tip Ranks·
    HK
    09606
    -1.07%

    Top 10 HK Stock Gainers (1.5)

    NANJING PANDA(00553) rose 39.75%, with a trading turnover 1.6 Billion HKD, and a year-to-date rose 48.7%. NUOBIKAN(02635) rose 21.6%, with a trading turnover 41.9 Million HKD, and a year-to-date rose 12.3%. MICROPORT NEURO(02172) rose 19.73%, with a trading turnover 942.5 Million HKD, and a year-to-date rose 24.4%.

    Top Gainers & Losers·
    HK
    00553
    -2.81%
    HK
    02635
    +8.92%
    HK
    02172
    -2.34%
    Top Gainers & Losers·
    HK
    00553
    -2.81%
    HK
    02635
    +8.92%
    HK
    02172
    -2.34%

    Morning Trend | DUALITYBIO's funds shrink again, is there a chance for a sector reversal on the way?

    On December 29th, DUALITYBIO-B was under pressure throughout the day, with funds continuously observing around the range of 10.3-10.5 yuan. The biopharmaceutical sector as a whole is experiencing a volume contraction and consolidation, lacking significant positive news for the industry, leading investors to mainly adopt a wait-and-see approach in the short term. The MACD short-term moving average death cross signal persists, making it difficult to change the weak technical pattern for now. Leading pharmaceutical companies have not launched new drugs or secured cooperation orders, resulting in decreased market interest in short-term rotation speculation. Large funds are more focused on policy and industry conference developments. If there is a breakout with increased volume during the trading session, it may attract short-term speculative funds; otherwise, the weak oscillation situation will continue, and risks need to be continuously monitored

    Technical Forecast·
    HK
    09606
    -1.07%
    Technical Forecast·
    HK
    09606
    -1.07%

    Top 10 HK Stock Losers (12.24)

    IVD MEDICAL(01931) fell 7.88%, with a trading turnover 11.3 Million HKD, and a year-to-date rose 23.3%. MINIEYE(02431) fell 7.62%, with a trading turnover 202.0 Million HKD, and a year-to-date fell 36.5%. ALPHAMAB-B(09966) fell 7.3%, with a trading turnover 13.8 Million HKD, and a year-to-date rose 197.7%.

    Top Gainers & Losers·
    HK
    01931
    -7.03%
    HK
    02431
    -3.78%
    HK
    09966
    -1.79%
    Top Gainers & Losers·
    HK
    01931
    -7.03%
    HK
    02431
    -3.78%
    HK
    09966
    -1.79%
    Posts
    View More

    $LEADS BIOLABS-B(09887.HK) Let's go all in $DUALITYBIO-B(09606.HK) hoping to replicate the trend.

    • 0
    © 2026 Longbridge｜Disclaimer